glp-1 without diabetes receptor agonism: a transformative approach for managing type-2 and obesity | Saudi Pharmaceutical Journal Taking GLP‑1 Without Diabetes in

Orforglipron significantly improved those parameters compared with controls

Gastrointestinal intolerance, particularly nausea and vomiting, may affect adherence despite their tendency to diminish over time ( Looking ahead, the future of GLP-1based therapy will depend on addressing safety concerns, improving long-term adherence, and expanding clinical indications

The experts agreed that GI AEs should be the main topic to focus on when addressing the optimal medical care of patients treated with GLP-1 RA

The severity of bloating varies considerably among individuals and may correlate with dietary choices, eating patterns, and the specific medication prescribed

[DOI] [PubMed] [Google Scholar] 211.Morgan-Bathke M., Raynor H.A., Baxter S.D., Halliday T.M., Lynch A., Malik N., Garay J.L., Rozga M

Find the right dose of weight loss medication for you by consulting with a qualified medical practitioner through Klinic